Authors
Latest:
Longhorn Vaccines Develops Sepsis Vaccine Targeting Key ToxinsThis composite peptide vaccine targets key bacterial toxins to prevent sepsis, enhance antibiotic efficacy, reduce inflammation in diseases and cancer, with further data expected soon.
Latest:
Identifying Disparities in Sepsis Diagnosis for Unbiased CareRisk of inaccuracy with pulse oximeters and clinician knowledge gaps in people of color may affect sepsis evaluations and impact treatment plans.
Latest:
Future Directions for Managing COVID-19 and InfluenzaGeorge Loukatos, MD, shares clinical pearls for the management of the SARS-CoV-2 and influenza viruses.
Latest:
Challenges in the Management of Mycobacterium abscessus ComplexThis pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.
Latest:
Cabotegravir Combined With Broadly Neutralizing Antibodies Maintains Undetectable HIVIn a long-acting dose regimen, an investigational antibodies treatment is a potent antiviral that can function as a component of a complete antiretroviral regimen.
Latest:
Contemporary Issues on the Treatment of Women Living with HIV in the USThe increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.
Latest:
From Pandemic to EndemicA research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.
Latest:
So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
Latest:
The ART of Implementing an Antiretroviral Stewardship ProgramBy addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.
Latest:
cUTI Roundtable: The Latest Therapeutic DevelopmentsThe third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.
Latest:
What We Know But Still Have to Learn About Long COVIDDespite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
Latest:
A Long-Acting Injectable for the Treatment of Candida spp InfectionsIn the second installment of a 3-part series on long-acting injectables related to various infections, Caitlin Soto, PharmD, BCIDP, provides insights on using rezafungin for invasive candidiasis.
Latest:
Rifaquizinone: A Novel Rifamycin-Quinolone Hybrid AntibioticRifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.
Latest:
Decoding Malaria Parasites to Aid in Potential Treatments and VaccinesThe Johns Hopkins Malaria Research Institute’s work in this area is looking to find ways to identify, for the first time, every single gene in the genome of malaria parasites, which could lead to the development of new treatments or vaccines.
Latest:
Molecular Diagnostics for Bacterial Pneumonia Need Testing StewardshipOngoing education and proven outcomes need to aid this form of testing.
Latest:
An Update on LenacapavirThis new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.
Latest:
mRNA COVID-19 Vaccines and Turbo Cancer: The Latest Myth That Won’t DisappearThe continuation of misinformation and disinformation being disseminated in the public is causing more public health communication issues as mistruths associate the vaccines with cancer.
Latest:
To Prophylax or not to Prophylax: Preventing CDIClinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).
Latest:
From Pathogen to Infectious Disease Diagnosis: Test Determines Between Bacterial and Viral Infections in 15 MinutesMeMed CEO Eran Eden, PhD, discusses the MeMed BV test and how it can help make the distinction between the types of infections, aid in patient management, and reduce antimicrobial resistance.
Latest:
What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility TestingThe Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
Latest:
So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
Latest:
AI as a Tool to Support Clinicians, Not Replace ThemSharmeen Roy, PharmD, BCPS, on artificial intelligence (AI) in improving decision-making, reducing adverse drug events on National Adverse Drug Event Awareness Day, and upcoming research on pediatric dosing at the the Congress of the European Society of Clinical Microbiology and Infectious Diseases.
Latest:
Outpatient Antimicrobial Stewardship: The Keys to Developing a Successful ProgramThis form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.
Latest:
Going Viral on Social Media: Integrating Digital Tools into Pharmacy RotationsIn the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.
Latest:
Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Latest:
While Hospital-Acquired C difficile Cases Have Decreased, Community-Acquired Cases Have RisenJoseph Zackular, PhD highlights targeting high-risk groups for vaccination and shares insights into the future of mRNA vaccine development for C diff.
Latest:
Tricky Infusion Issues and Potential Solutions: OPAT EditionOutpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.
Latest:
Treating Zaire ebolavirus With Ansuvimab-zyklThe recombinant human IgG1κ monoclonal antibody binds and neutralizes the virus.
